Key Takeaways AZN's oncology sales hit $5.6B in Q1 2025, up 13%, led by drugs like Tagrisso, Imfinzi, and Enhertu. Truqap and Datroway launches in HR HER2- breast cancer show early sales strength and FDA momentum. AZN eyes pipeline growth with late-stage drugs camizestrant and volrustomig across multiple cancer types.AstraZeneca (AZN) is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 41% of AstraZeneca‘s total revenues) rose 13% in the first quarter of 2025, generat ...

Key Takeaways SMMT surged after reports of AstraZeneca exploring a $15 billion licensing deal for ivonescimab. The deal may include billions upfront, with milestone payments tied to Ivonescimab's progress. Ivonescimab showed superiority over Keytruda and Tevimbra in late-stage NSCLC trials.Shares of clinical-stage company Summit Therapeutics (SMMT) rose nearly 9% on Thursday following a report issued by Bloomberg, which stated that pharma giant AstraZeneca (AZN) is in discussions with the company for a po ...

多个新药有望参与谈判 本周新药行情回顾： 2025 年 6 月 30 日-2025 年 7 月 4 日，新药板块涨幅前 5 企业：神州 细胞（45.00%）、圣诺医药（36.30%）、前沿生物（30.60%）、微芯 生物（30.50%）、康方生物（25.50%）；跌幅前 5 企业：欧康维视（- 12.90%）、科济药业（-9.10%）、东曜药业（-6.70%）、乐普生物（- 6.40%）、益方生物（-3.60%）。 2025 年 07 月 06 日 生物医药Ⅱ 新药周观点：25 年医保调整工作启动， 本周新药行业重点分析： 本周，国家医保局公布《2025 年国家基本医疗保险、生育保险和工伤 保险药品目录及商业健康保险创新药品目录调整工作方案（征求意见 稿）》及申报指南等文件的公告，2025 年医保目录调整工作有序开 始。根据上述文件，2020 年 1 月 1 日至 2025 年 6 月 30 日期间经国 家药监部门批准的新通用名药品可以申报参加 2025 年医保目录调 整。考虑到 2024 年的规则同样为 2024 年 6 月 30 日前获批新通用名 药品可以申报参加，因此预计 2025 年新增谈判药物将主要 ...

Core Insights - AbbVie has established a significant oncology franchise, expanding from blood cancer drugs to include therapies for solid tumors, with five oncology products now available [1][7] - The oncology segment contributed over 12% to AbbVie's total revenues in Q1 2025, with expectations for Emrelis, its first internally developed lung cancer drug, to start contributing in Q3 2025 [1][2][7] Company Strategy - AbbVie is pursuing both organic and inorganic growth strategies, with recent additions to its oncology portfolio coming from acquisitions and collaborations, while Emrelis represents an internal development [2] - The company has a diverse pipeline of promising therapies, including etentamig for multiple myeloma and Temab-A for colorectal and gastroesophageal cancers, indicating a strong focus on expanding its oncology offerings [3][7] Competitive Landscape - Major competitors in the oncology space include AstraZeneca, Merck, and Pfizer, with AstraZeneca's oncology sales accounting for nearly 41% of its total revenues and growing by 13% in Q1 2025 [4] - Merck's Keytruda accounted for over 46% of its total revenues in Q1 2025, while Pfizer's oncology revenues grew by 7%, making up over 27% of its total revenues [5] Financial Performance - AbbVie shares have outperformed the industry year to date, although the company's valuation is not considered cheap, trading at a P/E ratio of 13.99 compared to the industry average of 14.81 [6][9] - The Zacks Consensus Estimate for AbbVie's earnings has increased for both 2025 and 2026, indicating positive market sentiment [10]

Key Takeaways PFE's non-COVID revenues are rising, fueled by new drugs, key in-line products and Seagen acquisition. The Seagen deal added four ADCs to PFE's oncology portfolio, boosting revenues in 2024 and early 2025. PFE shares trade at a forward P/E of 7.97, well below the industry average and its 5-year historical mean.With the end of the pandemic, sales of Pfizer’s (PFE) COVID products, Comirnaty and Paxlovid, have declined. Though COVID revenues are declining, Pfizer’s non-COVID operational revenue ...

AstraZeneca (AZN) stock has declined 6.4% in the past three months.Although AstraZeneca faces its share of challenges, a significant portion of this price decline is attributed to broader market uncertainties and a volatile macroeconomic environment.The sky-high tariffs imposed by the United States and retaliatory tariffs by China and some other countries hurt global stock markets. Though the massive tariffs imposed by the United States and China are now on a pause, it is only a temporary suspension, and no ...

Core Earnings and Revenue Performance - AstraZeneca's first-quarter 2025 core earnings were $1.24 per American depositary share (ADS), exceeding the Zacks Consensus Estimate of $1.10, with core earnings of $2.49 per share reflecting a 21% year-over-year increase at constant exchange rates (CER) [1][2] - Total revenues reached $13.59 billion, a 7% increase on a reported basis and 10% at CER, although this figure fell short of the Zacks Consensus Estimate of $13.68 billion [2] Product Sales and Therapeutic Areas - Product sales increased by 9% to $12.88 billion, driven by strong demand for marketed products [3] - Oncology product sales rose 13%, while Cardiovascular, Renal and Metabolism (CVRM) product sales increased by 12%, and Respiratory & Immunology (R&I) segment sales grew by 11%. However, sales in the Rare Disease segment remained flat, and Vaccines & Immune (V&I) Therapies saw a decline of 30% [4] Collaboration Revenues - Collaboration revenues totaled $74 million, a 64% increase attributed to a sales milestone for Farxiga in Japan, while alliance revenues rose 42% to $639 million, driven by growth from partnered medicines [5][6] Key Drug Performance - Tagrisso sales reached $1.68 billion, up 8%, surpassing estimates [7] - Lynparza sales increased by 5% to $726 million but missed estimates due to soft performance in emerging markets and U.S. headwinds [8][9] - Imfinzi generated $1.26 billion in sales, up 16%, but also missed estimates [9] - Calquence sales rose 8% to $762 million, beating estimates [10] - New drug Truqap recorded $132 million in revenues, down from the previous quarter due to Medicare Part D redesign impacts [11] Segment Performance - In the CVRM segment, Farxiga sales were $2.06 billion, up 16%, benefiting from label expansions [12] - Brilinta/Brilique sales decreased by 4% to $305 million, while new drug Wainua added $39 million in sales [13] - In the R&I segment, Symbicort sales declined by 3% to $723 million, and Pulmicort sales fell by 26% [14] - Fasenra recorded a 19% increase in sales to $418 million, exceeding estimates [15] - In the Rare Disease portfolio, Soliris sales fell 38% to $444 million, while Ultomiris revenues rose 25% to $1.05 billion [17] Cost and Guidance - Core selling, general and administrative expenses increased by 4% to $3.46 billion, while core research and development expenses rose 16% to $3.09 billion [19] - AstraZeneca maintained its 2025 guidance, expecting total revenues to grow by a high single-digit percentage at CER and core EPS to increase by a low double-digit percentage [20] Strategic Updates - AstraZeneca announced the discontinuation of the CAPItello-280 study for Truqap in metastatic castration-resistant prostate cancer [22] - The company received a positive recommendation for a label expansion involving Calquence for CLL treatment [23] - AstraZeneca plans to launch 20 new medicines by 2030, targeting $80 billion in total annual revenues by the end of the decade [29]

Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe. Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association bet ...